Baxter International announced that its executive vice president and chief financial officer, Joel Grade, will step down to focus on family matters, with his departure effective April 30, 2026. The company has named Anita Zielinski—who joined Baxter in 2025 as senior vice president, chief accounting officer, and controller—as interim chief financial officer. Grade will remain in an advisory capacity through the end of April, while Zielinski will retain her current responsibilities and oversee the company’s financial operations during the board’s search for a permanent replacement.
Baxter’s recent financial results illustrate the context for the leadership change. In the fourth quarter of 2025 the company reported earnings per share of $0.44, falling $0.09 short of the consensus estimate of $0.53, while revenue rose 8.0 % year‑over‑year to $2.97 billion, exceeding the $2.82 billion forecast. The prior year’s fourth‑quarter EPS of $0.58 beat expectations, and the first quarter of 2025 saw an adjusted diluted EPS of $0.55, also above guidance. For fiscal 2026 Baxter has reiterated its earnings guidance at $1.850 – $2.050 per share.
The Q4 2025 earnings miss was driven by a sharp compression in profitability: adjusted gross margin fell 900 basis points and operating margin declined 340 basis points year‑over‑year. The margin squeeze reflects higher input costs and pricing pressure in key segments, while the company’s cost‑control initiatives have not yet fully offset the pressure. The 8.0 % revenue growth, however, was largely supported by strong demand in core medical‑device categories, offsetting headwinds in legacy product lines.
Against this backdrop, management’s guidance for fiscal 2026 signals confidence in the company’s turnaround strategy. The EPS range of $1.850 – $2.050 reflects an expectation that the balance‑sheet strengthening and operational improvements underway will sustain profitability, even as margin pressures persist. The guidance also indicates that the board believes the interim CFO will maintain continuity in financial reporting and strategy during the transition.
Andrew Hider, Baxter’s president and chief executive officer, said, “Joel has supported Baxter through a period of significant transformation, and we greatly appreciate his contributions and partnership.” He added, “Baxter remains well positioned for value creation and continues to prioritize stabilizing the business, strengthening our balance sheet, and driving a culture of continuous improvement. I am confident that Anita and the Finance team will provide strong leadership to ensure this continuity during the transition.”
Baxter’s broader transformation includes the divestiture of its kidney‑care business in early 2025 and a focus on core medical‑device segments. The company has also secured FDA 510(k) clearance for its Novum IQ large‑volume infusion pump with Dose IQ Safety Software, underscoring its commitment to product innovation. These initiatives are intended to streamline operations, reduce non‑core exposure, and support long‑term growth.
Investors have remained cautious, citing the company’s 52‑week low and the ongoing margin pressures highlighted by the Q4 2025 results. The CFO transition is viewed as a stabilizing step that preserves continuity in financial strategy while the board seeks a permanent replacement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.